Publications by authors named "Corey L Snyder"
Cumulative life course impairment: Evidence for hidradenitis suppurativa.
J Eur Acad Dermatol Venereol
March 2025
Hidradenitis suppurativa (HS) adversely affects quality of life, education, work, relationships and mental health. The debilitating effects of HS can compound over a patient's lifetime and have lasting repercussions. The cumulative life course impairment (CLCI) model analyses the disease factors that could affect the life course trajectory of a patient, including effects on major life decisions and opportunities, such as relationships, career path, education and starting a family.
View Article and Find Full Text PDFBackground: In some hidradenitis suppurativa (HS) clinical trial study arms, there is an unexpected decline in efficacy between the penultimate visit and the prespecified primary endpoint week, which we have termed a "wobble."
Objective: We aimed to establish how often study arms in HS programs wobble.
Methods: In a retrospective review, we identified HS clinical trials listed on ClinicalTrials.
Article Synopsis
- - The IL-17 pathways play a key role in inflammatory skin conditions, especially hidradenitis suppurativa, which currently has adalimumab as the only FDA-approved treatment.
- - Secukinumab, an IL-17A inhibitor, has been effective for conditions like psoriasis and shows promising results for hidradenitis suppurativa in recent phase III clinical trials.
- - This article explores how secukinumab works and reviews its clinical efficacy and safety for managing hidradenitis suppurativa.
Article Synopsis
- * Factors contributing to the delay in diagnosis include female gender, non-white race, higher disease severity, and issues like misdiagnoses and stigma surrounding the disease.
- * Increasing awareness through social media and academic talks, alongside the development of new medications and better understanding of HS, could improve treatment satisfaction and access to effective therapies.